An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.

Forbes contributors publish independent expert analyses and insights. Ge Bai is professor of accounting & health policy at Johns Hopkins. The United States's dominance in biotech innovation is crucial ...

New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing ...

The opening session sets the context and intent for the Inaugural Summit: USA-Saudi Biotech Alliance, outlining the strategic ...

Amid the expected positive clinical trial results, Legend Biotech has also reiterated plans to achieve profitability in 2026.

A life sciences hub in Syracuse is getting a major upgrade as New York pushes to grow its biotechnology sector. Gov. Kathy ...

China and the U.S. are in a race for preeminence in biotechnology. The U.S. is still dominant in biology and life sciences research, but China is catching up fast. At the same time, Congress and the ...

AI as defined by the UK Intellectual Property Office (‘UK IPO’) and European Patent Office (‘EPO’) Applications of AI in biotechnology How biotechnology companies can leverage AI to drive innovation ...

More people need better medicines, and there is a rising demand for food and sustainable solutions. This is why governments and private investors are spending more on research and development in the ...

This series of meetings of experts, organized under the auspices of the Standing Committee on Advances and National Security Implications of Transdisciplinary Biotechnology, will bring together ...

DELRAY BEACH, Fla., Oct. 31, 2025 /PRNewswire/ -- According to MarketsandMarkets(TM), The agriculture biotechnology market is projected to grow from USD 92.19 billion in 2025 to USD 144.25 billion by ...